Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Safety and Efficacy of Psilocybin Therapy Compared to Low-dose Control in Reducing Depressive Symptoms in Patients With COPD, ALS, MS, or APD.

NCT06782724 is registered in ClinicalTrials.gov with University Medical Center Groningen as lead sponsor.

NCT NCT06782724
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06782724 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Safety and Efficacy of Psilocybin Therapy Compared to Low-dose Control in Reducing Depressive Symptoms in Patients With COPD, ALS, MS, or APD.
Lead sponsor
University Medical Center Groningen
Phase
Phase 2
Overall status
Recruiting
Start date
July 1, 2025
Completion date
January 1, 2028
Enrollment
108 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

als (amyotrophic lateral sclerosis), atypical parkinson disease, copd (chronic obstructive pulmonary disease), major depressive disorder (mdd), ms (multiple sclerosis)